Search
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalIt is combined with [Piperacillin] and [Ceftolozane] for the treatment of a variety of bacterial infections. … and mortality in hospitalized patients.
Mixtures: PIPERACILLINA E TAZOBACTAM MYLAN GENERICS, PIPERACILLINA E TAZOBACTAM MYLAN GENERICSCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesRescinnamine
go.drugbank.com/drugs/DB01180ApprovedRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.
Synonyms: Trimethoxy cinnamoyl reserpate de methylInternational brands: Tsuruselpi SOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigational[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved … In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease.
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalIt was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesGemifloxacin
go.drugbank.com/drugs/DB01155ApprovedInvestigationalGemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. … It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Categories: Topoisomerase II Inhibitors, 4-QuinolonesProducts: ONFACT 320 MG FİLM TABLET, 5 ADET, ONFACT 320 MG FİLM TABLET, 7 ADETEconazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Mixtures: Econazole Nitrate 1% / Niacinamide 4%, 071023 Econazole Nitrate 1% / Niacinamide 4%Categories: combinations of imidazole derivatives, Metabolic Side Effects of Drugs and SubstancesEucalyptol
go.drugbank.com/drugs/DB03852ApprovedInvestigationalNutraceuticalEucalyptol is naturally produced cyclic ether and monoterpenoid. Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. … It kills leukaemia cells in vitro.
Synonyms: 1,8-epoxy-p-menthane, 1,8-oxido-p-menthaneMixtures: Marcs Original, Marcs Blue MintBelumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines … [L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalresults in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. … Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older.
Synonyms: 3-(6-{[1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic acidCategories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inducers